The Hippo-Yes Association Protein Pathway in Liver Cancer

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr class="thead"><td align="left">Mice</td><td align="left">Liver defects</td><td align="center">Liver tumorigenesis</td><td align="center">Reference</td></tr><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr><td align="left">Double transgenic <br/>LAP1/tTA-YAP S127A</td><td align="left">Hepatocyte proliferation and increased liver size after activation of an inducible YAP transgene (reversible effect)</td><td align="center"> </td><td align="center">[<a href="/journals/grp/2013/187070/#B51">50</a>]</td></tr><tr><td align="left" colspan="4"><hr/></td></tr><tr><td align="left">Double transgenic <br/>ApoE/rtTA-YAP</td><td align="left">Hepatocytes are resistant to Fas-mediated apoptosis</td><td align="center">Lethal HCCs</td><td align="center">[<a href="/journals/grp/2013/187070/#B48">48</a>]</td></tr><tr><td align="left" colspan="4"><hr/></td></tr><tr><td align="left">Albumin-Cre YAP c/c</td><td align="left">Increased liver size<br/>Defects in hepatocyte survival and  bile duct development severely impaired</td><td align="center"> </td><td align="center">[<a href="/journals/grp/2013/187070/#B22">22</a>]</td></tr><tr class="table-tr"><td colspan="4"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Description of the different phenotypes resulting from YAP activation in mice.

Gastroenterology Research and Practice

tab2

Table 2

Table 2: The Hippo-Yes Association Protein Pathway in Liver Cancer 